| アブストラクト | The rapid and large-scale roll-out of new COVID-19 vaccines has led to unprecedented challenges in assessing vaccine safety. In 2021, the European Medicines Agency (EMA) processed about 1.7 million safety reports related to COVID-19 vaccines in the EudraVigilance (EV) database and identified more than 900 potential signals. Beyond the large amount of information to be processed, the evaluation of safety signals has faced several difficulties and limitations, both in the assessment of case reports and in the investigation of databases. The evaluation of a signal of corneal graft rejection (CGR) with Vaxzevria((R)) was no exception to this. In this commentary, we present the challenges encountered in making regulatory decisions in the context of evolving evidence and knowledge. The pandemic crisis emphasised the importance of quick and proactive communication to address the many questions and, above all, to ensure the transparency of safety data. |
|---|
| ジャーナル名 | Vaccines |
|---|
| Pubmed追加日 | 2023/5/27 |
|---|
| 投稿者 | Bizimungu, Christelle; Sabbe, Martine; Wuillaume, Francoise; Hamdani, Jamila; Koch, Philippe; Dogne, Jean-Michel |
|---|
| 組織名 | DG Post Authorisation-Federal Agency for Medicines and Health Products, 1210;Brussels, Belgium.;Department of Ophthalmology, Hopitaux Iris Sud-Site Ixelles, Reseau Chorus,;Universite Libre de Bruxelles (ULB), 1050 Brussels, Belgium.;Department of Pharmacy, Namur Research Institute for Life Sciences, Namur;Thrombosis and Hemostasis Center, University of Namur, 5000 Namur, Belgium. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37243058/ |
|---|
